Quiet on the insider front: nobody at Iovance Biotherapeutics, Inc. bought or sold IOVA shares at market prices this past year.
No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters. 292 investment managers listed IOVA in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jun 6, 2025 | Kirby Daniel Gordon | Executive Officer | Buy | 30,000 | $1.84 | $55K | SEC |
| May 27, 2025 | Puri Raj K. | Executive Officer | Buy | 5,600 | $1.74 | $10K | SEC |
| May 16, 2025 | Vogt Frederick G | CEO | Buy | 25,000 | $1.69 | $42K | SEC |
| Nov 14, 2024 | Maynard Ryan D | Director | Sell | 50,000 | $10.06 | $503K | SEC |
| Feb 20, 2024 | MCPEAK MERRILL A | Director | Buy | 250,000 | $9.15 | $2.3M | SEC |
| Feb 20, 2024 | Dukes Iain D. | Director | Buy | 32,000 | $9.15 | $293K | SEC |
| Feb 20, 2024 | Rothbaum Wayne P. | Director | Buy | 5,000,000 | $9.15 | $45.8M | SEC |
| Sep 19, 2023 | MCPEAK MERRILL A | Director | Buy | 10,000 | $5.56 | $56K | SEC |
| Sep 15, 2023 | Rothbaum Wayne P. | Director | Buy | 5,000,000 | $5.30 | $26.5M | SEC |
There were no open-market insider trades in IOVA in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
292 investment managers reported holding IOVA in SEC Form 13F filings for Q2 2026.
No congressional trades in IOVA were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).